Toggle Main Menu Toggle Search

Open Access padlockePrints

Evidence that G-quadruplexes form in pathogenic fungi and represent promising antifungal targets

Lookup NU author(s): Dr Alessandra Da Silva DantasORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© The Author(s) 2025.Fungi are estimated to cause the death of almost 4 million people annually, and we urgently need new drug targets to overcome antifungal resistance. We found that four-stranded nucleic acid structures called G-quadruplexes (G4s) could form within the critical priority fungal pathogen Aspergillus fumigatus. Sequences with the potential to form G4s could be found in genes involved in fungal growth, virulence, and drug resistance. This included cyp51A, which encodes the target of azoles. Notably, we observed the formation of both canonical and unusual acid-stabilised G4s in these sequences. We found that PhenDC3 (a G4-stabilising ligand) could refold DNA into antiparallel G4 structures in cyp51A that were associated with decreased transcription. PhenDC3 also had potent fungistatic activity, prevented germination, synergised with the antifungal amphotericin B in vitro and in vivo, and displayed low genotoxicity and cytotoxicity towards human cells. Interestingly, PhenDC3 had greater antifungal activity towards the pan-azole-resistant A. fumigatus TR34/L98H isolate, and another G4-stabiliser, pyridostatin, killed multi-drug-resistant Candida auris. Taken together, G4s represent a promising target for the development of antifungals with novel mechanisms of action.


Publication metadata

Author(s): Middleton G, Mahamud FO, Storer ISR, Williams-Gunn A, Wostear F, Abdolrasouli A, Barclay E, Bradford A, Steward O, Schelenz S, McColl J, Leze B, van Rhijn N, da Silva Dantas A, Furukawa T, Warren D, Waller ZAE, Bidula S

Publication type: Article

Publication status: Published

Journal: EMBO Molecular Medicine

Year: 2025

Pages: epub ahead of print

Online publication date: 17/11/2025

Acceptance date: 29/10/2025

Date deposited: 01/12/2025

ISSN (print): 1757-4676

ISSN (electronic): 1757-4684

Publisher: Springer Science and Business Media Deutschland GmbH

URL: https://doi.org/10.1038/s44321-025-00340-1

DOI: 10.1038/s44321-025-00340-1

Data Access Statement: The source data of this paper are collected in the following database record https://doi.org/10.5281/zenodo.17192248. The source data of this paper are collected in the following database record: biostudies:S-SCDT-10_1038-S44321-025-00340-1. Expanded view data, supplementary information, appendices are available for this paper at https://doi.org/10.1038/s44321-025-00340-1.

PubMed id: 41249737


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Academy of Medical Sciences SBF008\1046 and SBF0010\1140
Biotechnology and Biological Sciences Research Council BB/Y005058/1 and BB/W001616/1
NIHR Newcastle Biomedical Research Centre (BRC)
Royal Society Research Grant [RG \R2\232363]
Wellcome Trust 226408/Z/22/Z

Share